Results 61 to 70 of about 12,098 (189)

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target [PDF]

, 2013
Cholangiocarcinoma is the second most common primary liver cancer and responds poorly to existing therapies. Intrahepatic cholangiocarcinoma (ICC) likely originates from the biliary tree and develops within the hepatic parenchyma.
Davare, M. A., Druker, B. J., Klimstra, D. S., Lowe, S. W., Saborowski, A., Saborowski, M.   +5 more
core   +1 more source

The MBD7 complex promotes expression of methylated transgenes without significantly altering their methylation status. [PDF]

, 2017
DNA methylation is associated with gene silencing in eukaryotic organisms. Although pathways controlling the establishment, maintenance and removal of DNA methylation are known, relatively little is understood about how DNA methylation influences gene ...
Chen, Xuemei, Feng, Ying, Gao, Lei, Guo, Hongwei, Kim, Yun Ju, Law, Julie A, Le, Brandon, Li, Dongming, Li, Shaofang, Li, Shengben, Liu, Jinyuan, Liu, Li, Liu, Xigang, Mo, Beixin, Palanca, Ana Marie S, Vashisht, Ajay A, Wohlschlegel, James A, Won, So Youn, Wu, Xiuyun, Yang, Guodong, Zhao, Yuanyuan   +20 more
core   +3 more sources

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion

Frontiers in Oncology, 2022
ROS1-rearranged patients account for 1-2% of non-small cell lung cancer (NSCLC) cases. Approximately 10 fusion partners have been discovered, while clinical practice is actively generating knowledge of new ones and their therapeutic responses. Herein, we
Shuli Wei, Mangsha Hu, Yan Yang, Xiaojie Huang, Baizhou Li, Liren Ding, Pingli Wang   +6 more
doaj   +1 more source

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer [PDF]

, 2016
Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes.
Coyle, Vicky M., Graham, Donna M., Kennedy, Richard D., Wilson, Richard H.   +3 more
core   +3 more sources

Novel Discovery of ROS1:PPFIBP1 fusion protein in General Lymphatic Anomaly

Journal of Vascular Anomalies, 2023
Generalized lymphatic anomaly (GLA) is a morbid condition with few treatment options. Cure is currently not possible, and therefore, treatment is aimed at symptom relief, improving function, and slowing the progression of disease.
Angela Kadenhe-Chiweshe, Michael Baad, Shipra Kaicker, Susan Mathew, Bradley Pua, Shaun Steigman, Catherine McGuinn   +6 more
doaj   +1 more source

Liquid biopsy genotyping in lung cancer: ready for clinical utility? [PDF]

, 2017
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its ...
Chen, Yi-Lin, Ho, Chung-Liang, Huang, Wei-Lun, Lin, Chien-Chung, Su, Wu-Chou, Wei, Fang, Wong, David T, Yang, Szu-Chun   +7 more
core   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins [PDF]

Cancer Research, 2019
Abstract Chromosomal rearrangements involving receptor tyrosine kinases (RTK) are a clinically relevant oncogenic mechanism in human cancers. These chimeric oncoproteins often contain the C-terminal kinase domain of the RTK joined in cis to various N-terminal, nonkinase fusion partners.
Dana S. Neel, David V. Allegakoen, Victor Olivas, Manasi K. Mayekar, Golzar Hemmati, Nilanjana Chatterjee, Collin M. Blakely, Caroline E. McCoach, Julia K. Rotow, Anh Le, Niki Karachaliou, Rafael Rosell, Jonathan W. Riess, Robert Nichols, Robert C. Doebele, Trever G. Bivona   +15 more
openaire   +5 more sources

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level. [PDF]

, 2018
‘A picture is worth a thousand words’ is an idiom from the English language (‘borrowed’ from on old Chinese proverb) that conveys the notion that a complex idea can be succinctly and fully described by a single image. Never has this expression been truer
Andrén, PE, Caprioli, RM, Castellino, S, Charkoftaki, G, Duncan, MW, Goodwin, RJA, Johnson, CH, Rattray, NJW, Schey, KL, Shahidi-Latham, SK, Vasiliou, V, Veselkov, KA   +11 more
core   +3 more sources